Svenja Straßburg1, Carolin-Maria Linker2,3, Sebastian Brato4, Christoph Schöbel5, Christian Taube2, Jürgen Götze3, Florian Stehling6, Sivagurunathan Sutharsan2, Matthias Welsner2, Gerhard Weinreich2. 1. Department of Pneumology, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany. svenja.strassburg@rlk.uk-essen.de. 2. Department of Pneumology, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Germany. 3. Information Processing Lab, Faculty of Electrical Engineering, Information Engineering - TU Dortmund, Dortmund, Germany. 4. SWG Sportwerk GmbH & Co. KG, Dortmund, Germany. 5. Center of Sleep and Telemedicine, University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, Essen, Germany. 6. Pediatric Pulmonology and Sleep Medicine, Cystic Fibrosis Center, Children'S Hospital, University Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we consecutively enrolled pwCF who were referred to our hospital. We determined RR and heart rate (HR) by using the minimal-impact system VitaLog during the hospital stay. Furthermore, we performed spirometry and evaluated CRP. RESULTS: We included 47 patients: 20 with pulmonary exacerbation and 27 without. RR decreased in patients with exacerbation (27.5/min (6.0/min) vs. 24.4/min (6.0/min), p = 0.004) and in patients with non-exacerbation (22.5/min (5.0/min) vs. 20.9/min (3.5/min), p = 0.024). Patients with exacerbation showed higher RR than patients with non-exacerbation both at the beginning (p = 0.004) and at the end of their hospital stay (p = 0.023). During the hospital stay, HR did not change in the total cohort (66.8/min (11.0/min) vs. 66.6/min (12.0/min), p = 0.440). Furthermore, we did not find significant differences between patients with exacerbation and patients with non-exacerbation (67.0/min (12.5/min) vs. 66.5/min (10.8/min), p = 0.658). We observed a correlation of ρ = -0.36 between RR and FEV1. Moreover, we found a correlation of ρ = 0.52 between RR and CRP. CONCLUSION: In pwCF requiring intravenous therapy, respiratory rate is higher at their hospital admittance and decreased by the time of discharge; it is also associated with C-reactive protein. Monitoring RR could provide important information about the overall clinical conditions of pwCF.
BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we consecutively enrolled pwCF who were referred to our hospital. We determined RR and heart rate (HR) by using the minimal-impact system VitaLog during the hospital stay. Furthermore, we performed spirometry and evaluated CRP. RESULTS: We included 47 patients: 20 with pulmonary exacerbation and 27 without. RR decreased in patients with exacerbation (27.5/min (6.0/min) vs. 24.4/min (6.0/min), p = 0.004) and in patients with non-exacerbation (22.5/min (5.0/min) vs. 20.9/min (3.5/min), p = 0.024). Patients with exacerbation showed higher RR than patients with non-exacerbation both at the beginning (p = 0.004) and at the end of their hospital stay (p = 0.023). During the hospital stay, HR did not change in the total cohort (66.8/min (11.0/min) vs. 66.6/min (12.0/min), p = 0.440). Furthermore, we did not find significant differences between patients with exacerbation and patients with non-exacerbation (67.0/min (12.5/min) vs. 66.5/min (10.8/min), p = 0.658). We observed a correlation of ρ = -0.36 between RR and FEV1. Moreover, we found a correlation of ρ = 0.52 between RR and CRP. CONCLUSION: In pwCF requiring intravenous therapy, respiratory rate is higher at their hospital admittance and decreased by the time of discharge; it is also associated with C-reactive protein. Monitoring RR could provide important information about the overall clinical conditions of pwCF.
Authors: Aina M Yañez; Dolores Guerrero; Rigoberto Pérez de Alejo; Francisco Garcia-Rio; Jose Luis Alvarez-Sala; Miriam Calle-Rubio; Rosa Malo de Molina; Manuel Valle Falcones; Piedad Ussetti; Jaume Sauleda; Enrique Zamora García; Jose Miguel Rodríguez-González-Moro; Mercedes Franco Gay; Maties Torrent; Alvar Agustí Journal: Chest Date: 2012-12 Impact factor: 9.410
Authors: Insa Korten; Elisabeth Kieninger; Sophie Yammine; Giulia Cangiano; Sylvia Nyilas; Pinelopi Anagnostopoulou; Florian Singer; Claudia E Kuehni; Nicolas Regamey; Urs Frey; Carmen Casaulta; Ben D Spycher; Philipp Latzin Journal: J Cyst Fibros Date: 2018-07-27 Impact factor: 5.482
Authors: W R Perera; J R Hurst; T M A Wilkinson; R J Sapsford; H Müllerova; G C Donaldson; J A Wedzicha Journal: Eur Respir J Date: 2006-11-15 Impact factor: 16.671
Authors: Sarah Dietz-Terjung; Jan Geldmacher; Sebastian Brato; Carolin-Maria Linker; Matthias Welsner; Christoph Schöbel; Christian Taube; Jürgen Götze; Gerhard Weinreich Journal: Sleep Breath Date: 2020-04-15 Impact factor: 2.816
Authors: Nicholas Hart; Michael I Polkey; Annick Clément; Michèle Boulé; John Moxham; Frédéric Lofaso; Brigitte Fauroux Journal: Am J Respir Crit Care Med Date: 2002-07-01 Impact factor: 21.405